Scientists in Germany say they've developed a nasal vaccine that can prevent Covid-19 from taking hold in the nose and throat, two potential entry points for the virus into the body.
In experiments on hamsters, the vaccine showed "sterilizing immunity", blocking the virus's ability to replicate and causing illness. The vaccine uses a weakened but live form of the coronavirus, which closely mimics natural infection.
Researchers think this approach could be key to preventing future Covid-19 variants from emerging by boosting immune defenses in the mucous membranes that line the upper airways.
This method has been tried before, dating back to the 1870s when vaccines were developed against anthrax and rabies using live but weakened viruses. The German team's codon pair deoptimization technique further hobbles the virus, making it harder for cells to replicate.
However, experts caution that more testing is needed before this vaccine can be widely used. "We should be developing a pan-coronavirus vaccine that does induce mucosal immunity and that is long-lived," says Dr. Greg Poland of the Mayo Clinic.
While other nasal vaccines are already in use or nearing completion in clinical trials, their effectiveness data has not been published yet. At least four more nasal vaccines are currently being tested on humans, according to the World Health Organization's vaccine tracker.
The German team will be watching closely for results from another company's study using a similar approach. However, there is a concern that respiratory infections can prove difficult to target with inhaled vaccines.
This latest development comes as the US continues to grapple with Covid-19 cases, with hundreds of Americans still dying daily from the virus.
In experiments on hamsters, the vaccine showed "sterilizing immunity", blocking the virus's ability to replicate and causing illness. The vaccine uses a weakened but live form of the coronavirus, which closely mimics natural infection.
Researchers think this approach could be key to preventing future Covid-19 variants from emerging by boosting immune defenses in the mucous membranes that line the upper airways.
This method has been tried before, dating back to the 1870s when vaccines were developed against anthrax and rabies using live but weakened viruses. The German team's codon pair deoptimization technique further hobbles the virus, making it harder for cells to replicate.
However, experts caution that more testing is needed before this vaccine can be widely used. "We should be developing a pan-coronavirus vaccine that does induce mucosal immunity and that is long-lived," says Dr. Greg Poland of the Mayo Clinic.
While other nasal vaccines are already in use or nearing completion in clinical trials, their effectiveness data has not been published yet. At least four more nasal vaccines are currently being tested on humans, according to the World Health Organization's vaccine tracker.
The German team will be watching closely for results from another company's study using a similar approach. However, there is a concern that respiratory infections can prove difficult to target with inhaled vaccines.
This latest development comes as the US continues to grapple with Covid-19 cases, with hundreds of Americans still dying daily from the virus.